Document Top

Back to Ovarian Cancer

Safety profile of Avastin front-line in ovarian cancer

Safety data from the two large phase III trials of Avastin as front-line therapy in ovarian cancer, GOG-0218 and ICON7, demonstrate that Avastin has a manageable side-effect profile.

The two large phase III trials of front-line Avastin, GOG-0218 and ICON7, in which more than 2,000 women with ovarian cancer were treated with Avastin, have provided safety data for Avastin administered for a maximum of 15 months.1,2 These data show that

  • Avastin demonstrates manageable side effects both in combination with chemotherapy and when continued as a single agent1,2
  • The incidence of GI(Complete penetration of the wall of the stomach, small intestine or large bowel, resulting in intestinal contents flowing into the abdominal cavity) perforations is within the range observed in other tumour(An abnormal growth of cells, forming a mass of tissue) types.3

References

  1. Burger RA, Brady MF, Bookman MA, et al. N Engl J Med 2011;365:2473–83.
  2. Perren TJ, Swart AM, Pfisterer J, et al. N Engl J Med 2011;365:2484–96.
  3. Avastin Summary of Product Characteristics, 2012.

Back to Ovarian Cancer Back to top

x

You are now leaving the www.avastin.net website. Links to all external sites are provided as a resource to our visitors. Hoffmann-La Roche Inc. ("Roche") accepts no responsibility for the content of these sites. Roche does not control these sites, and the opinions, claims, or comments expressed on these sites should not be attributed to Roche, except where indicated. We recommend that you consult with your physician or other healthcare provider to obtain more information about any Roche prescription medication.

OK Cancel